HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Zenas BioPharma

Contributing Author

Recent Articles by Zenas BioPharma

Mar-27
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million ZBIO -17.82% GlobeNewswire
Mar-26
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock ZBIO GlobeNewswire
Mar-16
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Mar-16
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update ZBIO GlobeNewswire
Feb-20
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Feb-09
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 ZBIO GlobeNewswire
Feb-04
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 ZBIO GlobeNewswire
Jan-16
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Jan-05
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) ZBIO -51.86% GlobeNewswire
Dec-19
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO +17.10% ZBIO GlobeNewswire
Dec-15
Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus ZBIO -19.71% GlobeNewswire
Nov-12
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update ZBIO GlobeNewswire
Nov-11
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences ZBIO +8.41% GlobeNewswire
Oct-27
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis ZBIO +33.08% GlobeNewswire
Oct-08
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis ZBIO +24.22% GlobeNewswire
Sep-02
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million ZBIO +9.50% GlobeNewswire
Aug-26
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences ZBIO GlobeNewswire
Aug-12
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates ZBIO +6.68% GlobeNewswire
Jun-20
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
May-29
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference ZBIO +8.34% GlobeNewswire
May-15
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates ZBIO +12.21% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)